Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company

Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that. England’s National Institute for Health and Care Excellence has recommended the CAR-T med to treat adults with diffuse large B-cell lymphoma.